Ten years of infliximab: Its role in dermatology

European Journal of Pharmacology

Volumn 623, Issue SUPPL.1, 2009, Pages

  Mrowietz, Ulrich ^a   Reich, Kristian ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b DERMATOLOGIKUM HAMBURG   (Germany)

Author keywords

Infliximab; Psoriasis; Psoriasis severity and activity index (PASI); Safety; Tumor necrosis factor (TNF)

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NEUTRALIZING ANTIBODY; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ATOPIC DERMATITIS; CLINICAL TRIAL; COMORBIDITY; CROHN DISEASE; DEMYELINATING DISEASE; DERMATOLOGY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTERITIS; GASTROINTESTINAL TOXICITY; GENETIC SUSCEPTIBILITY; HEALTH CARE NEED; HUMAN; HYPERTENSION; IMMUNOPATHOGENESIS; LIVER TOXICITY; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS; LYMPHOMA; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; NAIL DISEASE; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; PYODERMA GANGRENOSUM; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION; SPONDYLOARTHROPATHY; SUPPURATIVE HIDRADENITIS; SYMPTOM; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ANIMALS; ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DERMATOLOGY; HUMANS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 71549145990     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.10.024     Document Type: Review

References (41)

1. Askling J., Fored C.M., Baecklund E., Brandt L., Backlin C., Ekbom A., Sundstrom C., Bertilsson L., Coster L., Geborek P., Jacobsson L.T., Lindblad S., Lysholm J., Ratapaa-Dahlqvist S., Saxne T., Klareskog L., and Feltelius N. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann. Rheum. Dis. 64 (2005) 1414-1420
2. Augustin M., Lange S., Wenninger K., Seidenglanz K., Amon U., and Zschocke I. Validation of a comprehensive Freiburg Life Quality Assessment (FLQA) core questionnaire and development of a threshold system. Eur. J. Dermatol 14 (2004) 107-113
3. Brooklyn T.N., Dunnill M.G., Shetty A., Bowden J.J., Williams J.D., Griffiths C.E., Forbes A., Greenwood R., and Probert C.S. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55 (2006) 505-509
4. Brimhall A.K., King L.N., Licciardone J.C., Jacobe H., and Menter A. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br. J. Dermatol. 159 (2008) 274-285
5. Capon F., Di Meglio P., Szaub J., Prescott N.J., Dunster C., Baumber L., Timms K., Gutin A., Abkevic V., Burden A.D., Lanchbury J., Barker J.N., Trembath R.C., and Nestle F.O. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum. Genet. 122 (2007) 201-206
6. Cargill M., Schrodi S.J., Chang M., Garcia V.E., Brandon R., Callis K.P., Matsunami N., Ardlie K.G., Civello D., Catanese J.J., Leong D.U., Panko J.M., McAllister L.B., Hansen C.B., Papenfuss J., Prescott S.M., White T.J., Leppert M.F., Krueger G.G., and Begovich A.B. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80 (2007) 273-290
7. Chaudhari U., Romano P., Mulcahy L.D., Dooley L.T., Baker D.G., and Gottlieb A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357 (2001) 1842-1847
8. Crown W.H., Bresnahan B.W., Orsini L.S., Kennedy S., and Leonardi C. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr. Med. Res. Opin. 20 (2004) 1929-1936
9. Feldman S.R., Gordon K.B., Bala M., Evans R., Li S., Dooley L.T., Guzzo C., Patel K., Menter A., and Gottlieb A. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo- controlled trial. Br. J. Dermatol. 152 (2005) 954-960
10. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., and Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006) 1735-1741
11. Gelfand J.M., Troxel A.B., Lewis J.D., Kurd S.K., Shin D.B., Wang X., Margolis D.J., and Strom B.L. The risk of mortality in patients with psoriasis: results from a population-based study. Arch. Dermatol. 143 (2007) 1493-1499
12. Gelfand J.M., Berlin J., Van Voorhees A., and Margolis D.J. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch. Dermatol. 139 (2003) 1425-1429
13. Gerdes S., Zahl V.A., Knopf H., Weichenthal M., and Mrowietz U. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br. J. Dermatol. 159 (2008) 1116-1123
14. Gottlieb A.B., Evans R., Li S., Dooley L.T., Guzzo C.A., Baker D., Bala M., Marano C., and Menter A. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 51 (2004) 534-542
15. Henseler T., and Christophers E. Disease concomitance in psoriasis. J. Am. Acad. Dermatol. 32 (1995) 982-986
16. Hongbo Y., Thomas C.L., Harrison M.A., Salek M.S., and Finlay A.Y. Translating the science of quality of life into practice: what do dermatology quality of life index scores mean?. J. Invest. Dermatol. 125 (2005) 659-664
17. Katugampola R.P., Hongbo Y., and Finlay A.Y. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. Br. J. Dermatol. 152 (2005) 1256-1262
18. Keystone E.C. Advances in targeted therapy: safety of biological agents. Ann. Rheum. Dis. 62 Suppl 2 (2003) ii34-ii36
19. Ko J.M., Gottlieb A.B., and Kerbleski J.F. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J. Dermatol. Treat. 20 (2009) 100-108
20. Ludwig R.J., Herzog C., Rostock A., Ochsendorf F.R., Zollner T.M., Thaci D., Kaufmann R., Vogl T.J., and Boehncke W.H. Psoriasis: a possible risk factor for development of coronary artery calcification. Br. J. Dermatol. 156 (2007) 271-276
21. Marcil I., and Stern R.S. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 358 (2001) 1042-1045
22. Miller D.W., and Feldman S.R. Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert. Opin. Pharmacotherapy. 7 (2006) 157-167
23. Mrowietz U., Elder J.T., and Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch. Dermatol. Res. 298 (2006) 309-319
24. Mukhtar R., Choi J., and Koo J.Y. Quality-of-life issues in psoriasis. Dermatol. Clin. 22 (2004) 389-395
25. Nestle F.O., Kaplan D.H., and Barker J. Psoriasis. N. Engl. J. Med. 361 (2009) 496-509
26. Newland M.R., Weinstein A., and Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int. J. Dermatol. 41 (2002) 449-452
27. Patel R.V., Clark L.N., Lebwohl M., and Weinberg J.M. Treatments for psoriasis and the risk of malignancy. J. Am. Acad. Dermatol. 60 (2009) 1001-1017
28. Paul C., Ho V.C., McGeown C., Christophers E., Schmidtmann B., Guillaume J.C., Lamarque V., and Dubertret L. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J. Invest. Dermatol. 120 (2003) 211-216
29. Peters M.J., van der Horst-Bruinsma I.E., Dijkmans B.A., and Nurmohamed M.T. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin. Arthritis Rheum. 34 (2004) 585-592
30. Radtke M.A., Reich K., Blome C., Rustenbach S., and Augustin M. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J. Eur. Acad. Dermatol. Venereol. 23 (2009) 683-691
31. Rapp S.R., Feldman S.R., Exum M.L., Fleischer Jr. A.B., and Reboussin D.M. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. 41 (1999) 401-407
32. Reich K., Nestle F.O., Papp K., Ortonne J., Evans R., Guzzo C., Li S., Dooley L.T., Griffiths C.E.M., and for the EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374
33. Reich K., Nestle F.O., Papp K., Ortonne J.P., Wu Y., Bala M., Evans R., Guzzo C., Li S., Dooley L.T., and Griffiths C.E.M. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate- to-severe psoriasis: a randomized controlled trial. Br. J. Dermatol. 154 (2006) 1161-1168
34. Reich K., Sinclair R., Roberts G., Griffiths C.E., Tabberer M., and Barker J. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. Curr. Med. Res. Opin. 24 (2008) 1237-1254
35. Rich P., Griffiths C.E., Reich K., Nestle F.O., Scher R.K., Li S., Xu S., Hsu M.C., and Guzzo C. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J. Am. Acad. Dermatol. 58 (2008) 224-231
36. Rott S., and Mrowietz U. The use of infliximab in dermatology. J. Dtsch. Dermatol. Ges. 5 (2007) 655-660
37. Schmick K., and Grabbe J. Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab). Br. J. Dermatol. 150 (2004) 367
38. Schmitt J., Zhang Z., Wozel G., Meurer M., and Kirch W. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta- analysis of randomized controlled trials. Br. J. Dermatol. 159 (2008) 513-526
39. Sohn S., Schoeffski O., Prinz J., Reich K., Schubert E., and Waldorf K. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 212 (2006) 137-144
40. Sterry W., Barker J., Boehncke W.H., Bos J.D., Chimenti S., Christophers E., De la Brassine M., Ferrandiz C., Griffiths C., Katsambas A., Kragballe K., Lynde C., Menter A., Ortonne J.P., Papp K., Prinz J., Rzany B., Ronnevig J., van de Kerkhof P., and Voorhees J. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br. J. Dermatol. 151 Suppl 69 (2004) 3-17
41. Wilson F.C., Icen M., Crowson C.S., McEvoy M.T., Gabriel S.E., and Kremers H.M. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 61 (2009) 233-239